Coya Therapeutics Future Growth

Future criteria checks 2/6

Coya Therapeutics's earnings are forecast to decline at 56.1% per annum while its annual revenue is expected to grow at 54.4% per year. EPS is expected to decline by 29.6% per annum.

Key information

-56.1%

Earnings growth rate

-29.6%

EPS growth rate

Biotechs earnings growth	24.8%
Revenue growth rate	54.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	10 May 2024

Recent future growth updates

Recent updates

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Jan 13

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17

Earnings and Revenue Growth Forecasts

NasdaqCM:COYA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	30	N/A	N/A	N/A	1
12/31/2025	7	-28	N/A	N/A	2
12/31/2024	5	-16	N/A	N/A	2
3/31/2024	6	-10	-6	-5	N/A
12/31/2023	6	-8	-12	-11	N/A
9/30/2023	N/A	-12	-12	-11	N/A
6/30/2023	N/A	-13	-11	-11	N/A
3/31/2023	N/A	-13	-10	-9	N/A
12/31/2022	N/A	-12	-8	-7	N/A
9/30/2022	N/A	-11	-6	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-6	-5	-5	N/A
12/31/2021	N/A	-5	-4	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: COYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: COYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: COYA's revenue (54.4% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: COYA's revenue (54.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if COYA's Return on Equity is forecast to be high in 3 years time

Coya Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 64%, EPS downgraded

Consensus revenue estimates increase by 100%

Recent updates

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis

New minor risk - Share price stability

Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

New major risk - Financial position

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)

Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory Board

Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the study

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. has completed an IPO.

High number of new and inexperienced directors

Coya Therapeutics, Inc. has completed an IPO.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies